Korea approves Mounjaro for cardiovascular risk reduction and kids with type 2 diabetes
The MFDS approval rests on SURPASS-CVOT, where Mounjaro matched Trulicity on heart events in 13,000+ patients but did not prove superior.
Recap by typeshit. Full story at Korea Biomedical Review.